<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779271</url>
  </required_header>
  <id_info>
    <org_study_id>Plb CD 301 Version 3.10</org_study_id>
    <nct_id>NCT01779271</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Pelubiprofen &amp; Loxoprofen in Patients With Upper Respiratory Tract Infection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      Multi-center, Randomized, Double blind, Controlled Parallel-group Comparative Phase 3
      Clinical trial to assess the efficacy and safety of Pelubiprofen Compared to Loxoprofen in
      patients with Acute upper respiratory infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Body temperature from baseline</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6 Hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Acute Upper Respiratory Infection</condition>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Pelubiprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Loxoprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubiprofen</intervention_name>
    <arm_group_label>Pelubiprofen</arm_group_label>
    <other_name>Pelubiprofen 30 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loxoprofen</intervention_name>
    <arm_group_label>Loxoprofen</arm_group_label>
    <other_name>Loxoprofen 60mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 15 years old

          2. Male and Female

          3. Patients with fever over 38.0Â°C due to cold (acute upper respiratory tract infection)

          4. Patients with upper respiratory tract infection outbreak within 2 days and who did not
             received drug administration

          5. Subjects who voluntarily or legal guardian agreed with written consent

        Exclusion Criteria:

          1. Fever reducer administration Within 4 hours from the screening point

          2. Any incidence of febrile crisis from the past six months

          3. Patients with Ulcers, gastrointestinal disorders which are confirmed by endoscopy

          4. Patients with continuously administrating gastrointestinal disorder related drug

          5. Patients with severe blood damage

          6. Severe hepatic impairment (ALT, AST value more than 2 times the upper limit of the
             normal range)

          7. With severe renal impairment (serum creatinine value is more than 2 times the upper
             limit of the normal range)

          8. Patients with severe left ventricular dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ang University Hospital, South Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelubi</keyword>
  <keyword>Pelubiprofen</keyword>
  <keyword>Loxoprofen</keyword>
  <keyword>Anti-pyretic</keyword>
  <keyword>Fever</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

